Peroxisome proliferator-activated receptors as molecular targets in relation to obesity and Type  2 diabetes

The three isotypes of peroxisome proliferator-activated receptors (PPARs) are currently perceived as major regulatory nodes (or hubs) of metabolic pathway networks, linking most prevalent diseases including Type  2 diabetes, obesity, dyslipidemia and atherosclerosis. The integrative functions of PPA...

Full description

Saved in:
Bibliographic Details
Published inPharmacogenomics Vol. 8; no. 6; pp. 587 - 596
Main Author SSEda, OndøørrEj
Format Journal Article
LanguageEnglish
Published England Future Medicine Ltd 01.06.2007
Subjects
animal models
Animals
Anti-Obesity Agents - administration & dosage
Atherosclerosis
Development and progression
Diabetes Mellitus, Type 2 - genetics
Diabetes Mellitus, Type 2 - metabolism
Diabetes Mellitus, Type 2 - therapy
Drug Delivery Systems - methods
ecogenetics
Gene Targeting - methods
Genetic Variation - drug effects
Genetic Variation - genetics
glitazar
GW501516
Humans
metabolic syndrome
Obesity
Obesity - genetics
Obesity - metabolism
Obesity - therapy
Peroxisome Proliferator-Activated Receptors - agonists
Peroxisome Proliferator-Activated Receptors - genetics
Pharmacogenetics
pioglitazone
rosiglitazone
Type 2 diabetes
Type  2 diabetes
Online AccessGet full text

Cover

More Information
Summary:The three isotypes of peroxisome proliferator-activated receptors (PPARs) are currently perceived as major regulatory nodes (or hubs) of metabolic pathway networks, linking most prevalent diseases including Type  2 diabetes, obesity, dyslipidemia and atherosclerosis. The integrative functions of PPARs are also reflected in their ecogenetic profile, when the variants underlying pharmacogenetic interactions were also shown to modulate the effect of lifestyle factors. Despite their extensive clinical use, there are many outstanding issues, especially concerning their safety. Critical pharmacogenomic assessment is warranted for the new potent ligands of multiple PPAR isoforms as many have displayed serious side-effects in a limited number of treated subjects. Nevertheless, the advent of genomic, transcriptomic and system biology-level approaches, integrating knowledge from model systems and human biology, should greatly facilitate the transition to individualized PPAR-based therapies.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Review-1
ObjectType-Article-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1462-2416
1744-8042
1744-8042
DOI:10.2217/14622416.8.6.587